AffyImmune Raises $30 Million for CAR-T Therapies from HK Investor
October 07, 2021 at 05:14 AM EDT
AffyImmune Therapeutics of Massachusetts closed a $30 million Series A+ round from a single firm, ORI Capital, a Hong Kong healthcare investor. AffyImmune is a clinical stage CAR T developer focused on developing CAR T therapies for solid tumors. The company uses its proprietary tracking platform to tune the affinity of CAR T cells. The goal is reduce toxicity and increase CAR T cell longevity while allowing in vivo monitoring. The capital will be used to advance the Phase 1 study of AffyImmune's lead asset to treat specific types of thyroid cancer. More details.... Share this with colleagues: // //